Bristol-Myers, Clovis leap into PhIII combo studies in a PD-1/PARP play as rivals circle
The checkpoint combo deal frenzy continues this morning with a tie-up between Bristol-Myers Squibb and Clovis that will marry their PD-1/PARP drugs and leap straight into Phase III registration studies.
As we learned again at the end of last week, as AstraZeneca buckled under the weight of a failed primary endpoint in its in-house combination study of durvalumab and tremelimumab, pivotal combination bets loom large these days as key players race to conquer — or stay ahead of — a megamarket. This time Clovis will look to quickly check intense rivalry from Tesaro and AstraZeneca in the PARP business, with Bristol-Myers coming along as a partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
